<DOC>
	<DOC>NCT01375478</DOC>
	<brief_summary>This open-label, retrospective, observational study will evaluate the compliance to RoActemra/Actemra (tocilizumab) therapy in patients with moderate to severe rheumatoid arthritis. Six months data will be collected from patients records.</brief_summary>
	<brief_title>An Observational Study of RoActemra/Actemra in Patients With Moderate to Severe Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Adult patients, over 18 years of age Moderate to severe rheumatoid arthritis RoActemra/Actemra treatment must have been initiated 6 months prior to signing the informed consent form Patients with rheumatic autoimmune disease other than rheumatoid arthritis Patients who are not willing to sign the informed consent form Patients who participate in interventional trials during the period of this observational study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>